Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Brentuximab
vedotin
(
BV
)
is
an
antibody-drug
conjugate
that
targets
CD
30
-
positive
malignancies
via
an
anti-
CD
30
monoclonal
antibody
linked
to
monomethyl
auristatin
E
,
a
microtubule-disrupting
agent
,
by
a
protease-cleavable
linker
.
BV
has
received
accelerated
approval
from
the
US
Food
and
Drug
Administration
for
the
treatment
of
classical
Hodgkin
lymphoma
that
has
relapsed
either
after
autologous
stem
cell
transplantation
(
ASCT
)
or
after
two
lines
of
combination
chemotherapy
in
patients
ineligible
for
ASCT
,
and
in
systemic
anaplastic
large
cell
lymphoma
after
failure
of
at
least
one
line
of
multiagent
chemotherapy
.
Phase
I
studies
in
CD
30
-
positive
lymphomas
have
determined
the
maximum
tolerated
dose
to
be
1
.
8
mg
/
kg
intravenously
every
21
days
.
In
relapsed
/
refractory
Hodgkin
lymphoma
,
a
pivotal
Phase
II
study
of
single
-
agent
BV
showed
an
overall
response
rate
of
75
%
,
with
34
%
complete
responses
and
a
median
remission
duration
of
20
months
for
complete
responders
.
BV
has
a
modest
toxicity
profile
,
with
peripheral
neuropathy
as
one
of
the
most
clinically
significant
side
effects
,
and
this
is
largely
reversible
.
Therefore
,
BV
is
the
treatment
of
choice
for
patients
with
relapsed
/
refractory
Hodgkin
lymphoma
after
ASCT
or
two
standard
regimens
.
Ongoing
trials
are
evaluating
the
role
of
BV
as
salvage
therapy
prior
to
ASCT
and
for
maintenance
after
ASCT
for
patients
with
relapsed
/
refractory
disease
.
Diseases
Validation
Diseases presenting
"hodgkin lymphoma"
symptom
esophageal adenocarcinoma
hodgkin lymphoma, classical
monosomy 21
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
This symptom has already been validated
